<DOC>
	<DOCNO>NCT02811159</DOCNO>
	<brief_summary>To determine safety extend treatment Proellex woman successfully complete either study ZPV-201 ZPU-203 meet eligibility criterion .</brief_summary>
	<brief_title>An Extension Study 12 mg Proellex® ( Telapristone Acetate ) Administered Orally Treatment Premenopausal Women With Confirmed Symptomatic Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Completed either study ZPV201 ZPU203 Agreement attempt become pregnant trial Agreement use alcohol moderation record daily consumption ( note : elevate liver enzyme may result discontinuation study ) Ability complete daily subject diary study procedure compliance protocol Women childbearing potential must willing use doublebarrier contraception study offdrug interval . Acceptable doublebarrier method : male condom spermicide ; male condom diaphragm ; diaphragm contain spermicide plus additional intravaginal spermicide Has negative pregnancy test Visit 1 Subject available treatment followup visit Subject significant decrease bone mineral density participate ZPV201 ZPU203 ( total hip spine measurement decrease 5 % ) Subject undergone hysterectomy and/or bilateral oophorectomy since enrollment ZPV201 ZPU203 . Subject pregnant lactating attempt expect become pregnant entire study period Subjects abnormally high liver enzymes liver disease . ( ALT AST exceed 2 x ULN AND total bilirubin exceed 1.5 x ULN Visit 1 confirm repeat ) . Subject hemoglobin &lt; 7.5 g/dL Visit 1 Concurrent use testosterone , progestin , androgen , estrogen , anabolic steroid , DHEA hormonal product least 2 week prior Visit 1 Use oral contraceptive 30 day precede screening . Use DepoProvera® precede 10 month . Use GnRHas ( e.g . Lupron Depot ) within 3 month prior screen ( Lupron Depot must washout period 3 month prior screen ) Has IUD place Current cervical dysplasia classify Atypical Squamous Cells Undetermined Significance ( ASCUS ) associate highrisk human papilloma virus ( HPV ) Current diagnosis Low/High Grade Squamous Intraepithelial Lesion ( LGSIL HGSIL ) , endometrial polyp hyperplasia Observation history abnormal endometrial biopsy include presence EIN Recent history ( within past 6 month ) alcoholism drug abuse Endometrial stripe ≥18 mm thickness Visit 1 ( subject may enrol sponsor approval ) Subject currently take cimetidine spironolactone take last 30 day Clinically significant abnormal finding Visit 1 examination laboratory assessment condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>